Alkermes (ALKS) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Powered by 
Analysis
Alkermes (ALKS) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.34 Bn | 625.58 Bn | 17.26 Bn |
| 2 | AbbVie | 441.84 Bn | 435.27 Bn | 12.70 Bn |
| 3 | Merck | 366.20 Bn | 359.06 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.65 Bn | 258.96 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.41 Bn | 45.03 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 8 | Incyte | 25.52 Bn | 20.98 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.51 Bn | 18.85 Bn | 683.80 Mn |
| 10 | Alkermes | 7.56 Bn | 6.91 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.02% |
| Mar 31, 2026 | -24.30% |
| Dec 31, 2025 | 25.86% |
| Sep 30, 2025 | 261.75% |
| Jun 30, 2025 | 37.75% |
| Mar 31, 2025 | 20.88% |
| Dec 31, 2024 | 50.79% |
| Sep 30, 2024 | 30.23% |
| Jun 30, 2024 | 32.99% |
| Mar 31, 2024 | 18.91% |
| Dec 31, 2023 | 45.27% |
| Sep 30, 2023 | 27.28% |
| Jun 30, 2023 | 56.07% |
| Mar 31, 2023 | 4.92% |
| Dec 31, 2022 | 61.42% |
| Sep 30, 2022 | -12.02% |
| Jun 30, 2022 | 6.86% |
| Mar 31, 2022 | 12.22% |
| Dec 31, 2021 | 51.32% |
| Sep 30, 2021 | 14.29% |